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Adoptive cell transfer immunotherapy using tumor inﬁltrating lymphocytes (TILs) was an important therapeutic strategy against
tumors. But the eﬃcacy remains limited and development of new strategies is urgent. Recent evidence suggested that CpG-ODNs
might be a potent candidate for tumor immunotherapy. Here we ﬁrstly reported that CpG-ODNs could signiﬁcantly enhance the
antitumor eﬃcacy of adoptively transferred TILs in vivo accompanied by enhanced activity capacity and proliferation of CD8+
Tc e l l sa n dC D 8 + T cells, as well as a Th1 polarization immune response. Most importantly, we found that CpG-ODNs could
signiﬁcantly elevate the inﬁltration of Th17 cells in tumor mass, which contributed to anti-tumor eﬃcacy of TILs in vivo. Our
ﬁndings suggested that CpG ODNs could enhance the anti-tumor eﬃcacy of adoptively transferred TILs through modifying Th1
polarization and local inﬁltration of Th17 cells, which might provide a clue for developing a new strategy for ACT based on TILs.
1.Introduction
In the past decades, adoptive cell transfer (ACT) immuno-
therapyhasdevelopedintoanimportanttherapeuticstrategy
against tumors. Many attempts have been made to improve
the eﬃcacy of adoptively transferred cells [1]. It was
reported that adoptively transfer of tumor-speciﬁc T cell
receptors-engineered T cells clone could improve the eﬀect
of immunotherapy [2]. Other researchers further adoptively
transferred chimeric antigen receptor-engineered T cells into
tumor host for immunotherapy of cancer [3]. However, the
eﬃcacy of ACT was still limited. Recent evidence suggested
that tumor inﬁltrating lymphocytes (TILs) were the best
candidate for ACT because of their directed interaction with
tumor cells [4, 5]. However, the eﬃcacy of TILs-based ACT
wasalsointractable[6,7]. Thus, new strategies were required
for achieving eﬀective antitumor responses of ACT based
on TILs, which might ultimately aid the clinical therapy for
tumor patients.
CpG dinucleotides (CpG-ODNs) were strong activators
of both innate and adaptive immunity through activating
TLR9 molecule expressed on immunological cells such as
dendritic cells, macrophages, T cells, and B cells. Over the
pastyears,therehasbeenanenormousincreaseintheunder-
standing of the molecular and cellular eﬀects of CpG-ODNs,
whichhavebeenfoundtofunctionasTh-1adjuvant.Thisled
to the idea to utilize CpG-ODNs for induction of antitumor
immune response as an adjuvant therapeutic strategy [8, 9].2 Clinical and Developmental Immunology
Table 1: The clinical pathological characters of the patients with
lung cancer.
Clinical pathological parameter n
sex
Male 15
Female 11
Age (years) 18–72
Tumor stage
T1/2 12
T3/4 14
Nodal status
N0/1 15
N2/3 11
Histological type
NSCLC 21
SCLC 5
(1) Lymph nodal metastasis is according to pathological diagnosis and
clinical palpation;
(2) clinical stage is according to TNM stage.
Our previous study found that CpG-ODNs could enhance
the antitumor responses of peripheral blood mononuclear
cells (PBMCs) from human lung cancer patients [10].
However, the eﬀects of CpG-ODNs on ACT based on TILs
remain unclear, which might be useful for optimizing the
antitumor eﬃciency of adoptively transferred TILs and the
development of new strategies for ACT immunotherapy.
To address this issue, here we carefully evaluated the
eﬀect of CpG-ODNs on the antitumor eﬃcacy of transferred
TILs from human lung cancer patients. We demonstrated
that CpG-ODNs could eﬀectively enhance the antitumor
responses of TILs through elevating activity capacity and
proliferation of CD4+ and CD8+ Tc e l l s . Most impor-
tantly, we found that CpG-ODNs could modify the Th1
polarization and inﬁltration of Th17 cells in tumor mass.
Our ﬁndings suggested that CpG-ODNs could enhance the
antitumor responses of TILs, which could lead to a new
understanding of the role of CpG-ODNs on ACT to enhance
the antitumor eﬃcacy.
2.MaterialsandMethods
2.1. Patients. Between Jan 2007 and Sep 2009, we collected
tumor samples from patients with lung cancer in East Hos-
pital, Shanghai, China. The study group (n = 26) comprised
chemotherapy and radiotherapy naive patients with lung
cancer. All patients gave informed consent approved by the
local Ethics Committee. Review of pathology reports con-
ﬁrmed the diagnosis. Information regarding clinical patho-
logical characters of patients was summarized in Table 1.
2.2. Isolation of TILs. The lymphocytes were harvested from
tumors by a discontinuous density gradient method as
described previously [11] .B r i e ﬂ y ,t u m o r sw e r er e m o v e d
aseptically and minced with scissors into 1-2mm3 pieces.
The minced tumors were then stirred in 40mL complete
RPMI 1640 containing 40mg collagenase, type IV (Sigma),
4mg deoxyribonuclease (Sigma), and 100U hyaluronidase
(Sigma) for 3 hours at room temperature. The tumor cell
suspension was ﬁltered through a nylon-mesh screen with
pores of 50μm to remove cell clumps, and the ﬁltrate
was then centrifuged (250g, 10 minutes). The cell pellet
was washed and resuspended in complete RPMI 1640 (Life
Technologies, Gaithersburg, MD). A 4-mL aliquot of cell
suspension of disaggregated tumor was placed on top of the
gradient formed by overlapping a cushion of 100% Ficoll-
Paque (Pharmacia Fine Chemicals, Piscataway, NJ) with an
equal volume of 75% Ficoll-Paque in RPMI 1640. Gradients
(14mL) were centrifuged at 800g for 30 minutes at room
temperature. The cells were collected and washed three times
in fresh medium and resuspended in complete RPMI 1640
for future use.
2.3.Reagents. ThefollowingODNswereusedandpurchased
from Integrated DNA Technologies (Coralville, IO): CpG
ODN (ODN 2006) 5 -TCGTCGTTTTGTCGTTTTGTCGT
T-3 ; control, (ODN1612) GCTAGAGCTTAGGCT. CpG
ODN has a phosphorothioate backbone that provides a high
degree of nuclease resistance. All the other reagents were
purchased from Sigma-Aldrich unless stated otherwise.
2.4. Cell Preparations. The autologous tumor cells from
human lung cancer patients were prepared as previously
[10]. Cells were cultured in RPMI 1640, supplemented with
10% fetal bovine serum (FBS), penicillin/streptomycin, and
L-glutamine(allreagentspurchasedfromGibco-BRL,Grand
Island, NY).
2.5. Adoptive Cell Transfer. After stimulation with 10ug/mL
CpG-ODNs or control CpG-ODNs for 48 hours in the pres-
ence of 50U/mL rIL-2, TILs were collected respectively. 1 ×
107 cells/mouseTILsina0.2-mLvolumewereinjectedintra-
venously into tumor-bearing nude mice with corresponding
100mg CpG ODNs or control CpG ODNs, respectively.
Tumorgrowthweremeasuredatindicatedtimes.Subsequent
to adoptive transfer in vivo, bulk lymphocytes were isolated
from tumors at the indicated time points.
2.6. Evaluation of Tumor Growth. Evaluation of tumor
growth was performed as described previously with minor
modiﬁcations [10]. Brieﬂy, BALB/c nu/nu mice (6–8 weeks
old)wereinjectedsubcutaneouslywith0.2mLofasingle-cell
suspensioncontaining5×105 tumorcellsandkeptinlaminar
ﬂow cabinets under speciﬁc pathogen-free conditions. After
7 days, about 70% mice developed tumor and the mean
of tumor size was 6mm2.T h e n1× 107 autologous TILs
pretreated as above described in a 0.2-mL volume were
injected intravenously into tumor-bearing nude mice with
corresponding CpG ODNs or control CpG ODNs respec-
tively for the following experiments.
2.7. Flow Cytometry. Flow cytometry was performed on an
FACS Calibur (BD Biosciences) with CellQuest Pro softwareClinical and Developmental Immunology 3
using directly conjugated mAbs against the following mark-
ers: CD3-FITC, CD4-PerCP, CD8-allophycocyanin, CD62L-
PE, CD44-PE, IL-4-PE, or IFN-γ-PE with corresponding
isotype-matched controls (either BD Biosciences or eBio-
science Systems). Intracellular staining was run according to
the manufacturer’s protocol. To determine the percentage of
CD4+Th17cells,lymphocytesweregatedbyplottingforward
versus side scatter followed by gating on CD3+ CD4+ T cells,
and these cells were then analyzed for IL-17 expression.
2.8. In Vivo BrdU Labeling Proliferation. Four days after
adoptivecelltransfer,tumor-bearingnudemicewereadmin-
istrated with 2mg BrdU (5-bromo-2-deoxyuridine, Sigma)
i.p. every other day up to a cumulative dose of 8mg BrdU
as indicated. Eight hours after the last BrdU injection, CD4+
T cells and CD8+ T cells isolated from the tumor mass were
analyzed by ﬂow cytometry for the incorporation of BrdU as
described previously [12].
2.9. Detecting the Activated Phenotypes on Lymphocytes. Ten
days after adoptive cell transfer, tumors were sectioned and
cut into pieces and then suspended in RPMI1640 containing
1mg/mL collagenase IV for 4 hours. Lymphocytes inﬁltrated
in the tumors were isolated by loading onto Ficoll for
density gradient centrifugation. TILs were then directly con-
jugated with mAbs marked as CD3-FITC, CD4-PerCP, CD8-
Allophycocyanin, CD62L-PE, or CD44-PE. Flow cytometry
was performed on an FACS Calibur (BD Biosciences)
with CellQuest Pro software. To determine the activated
phenotype of T cells, lymphocytes were gated by plotting
forward versus side scatter followed by gating on CD3+CD4+
T cells or CD3+ CD8+ T cells. Gated cells were then analyzed
for CD44 and CD62L expression. The expression level of
CD44 and CD62L on lymphocytes analyzed by FACS was
shown as mean ﬂuorescence intensity (MFI).
2.10. Intracellular Staining for IFN-γ and IL-4. TILs were
harvested from tumor bearing nude mice and stained of
surface markers (CD8, CD4); cells were ﬁxed and permeabi-
lized using Cytoﬁx/Cytoperm and Perm/Wash buﬀer from
BDBiosciencesaccordingtothemanufacturer’sinstructions.
All antibodies to cytokines (IFN-γ and IL-4) including the
corresponding isotype controls were obtained from BD
Biosciences. Cells were stained with antibody against IFN-
γ or IL-4 (1:100) at 4◦C for 30 minutes and washed twice in
Perm/Wash before analysis.
2.11. Statistical Analyses. Statistical analyses of the data were
performed with the SPSS12.0 software. Data were analyzed
using a one-way analysis of variance (ANOVA) or Kruskal-
Wallis test with PRISM 4.0 (GraphPad Soft-ware Inc, San
Diego, CA, USA). ∗P<. 05 was considered statistically
signiﬁcant in all comparisons.
3. Results
3.1.CpG-ODNsTreatedTILsReducedTumorBurdenandPro-
longed Nude Mice Survival. I no r d e rt oe v a l u a t et h ee ﬀect of
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Figure 1: CpG-ODNs treated TILs reduced tumor burden and
prolongednudemicesurvival.TILswerecollectedfromlungcancer
patients (n = 26) and treated with CpG-ODNs or control CpG-
ODNs as described in Materials and Methods.1× 107 autologous
TILs were transferred into lung cancer bearing Balb/c nude mice
with 100ug CpG-ODNs or control CpG-ODNs through tail vein.
The tumor growth of each group was measured and the survival
timeoftumorbearingnudemicewascalculated.Onerepresentative
data from 26 individual patients with lung cancer was shown (a).
Each bar represents the means (±SD) from 6 nude mice in each
group. The survival rate from all 26 individual patients was also
calculated (b). ∗P<. 05.
CpG-ODNs on the antitumor eﬃcacy of ACT immunother-
apy, TILs isolated from human lung cancer patients were
adoptively transferred into autologous tumor bearing nude
mice with CpG-ODNs as described in Materials and Meth-
ods. Then the tumor growth and survival of tumor-bearing
mice were observed. As shown in Figures 1(a) and 1(b),
compared with control group, transferred autologous TILs
signiﬁcantly reduced the growth of tumor and prolonged the
survival of tumor-bearing mice (P<. 0 5 ) .I m p o r t a n t l y ,w e4 Clinical and Developmental Immunology
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Figure 2: CpG-ODNs altered the expression of CD62L and CD44 on CD4+ Tc e l l sa n dC D 8 + T cells. TILs were collected from lung cancer
patients (n = 16) and treated with CpG-ODNs or control CpG-ODNs as described in Materials and Methods.1× 107 autologous TILs were
transferred into the tumor bearing Balb/c nude mice with 100ug CpG-ODNs or control CpG-ODNs through tail vein. Ten days later, the
lymphocytes were isolated from tumor mass and the expression of CD62L (a) and CD44 (b) on CD4+ Tc e l l sa n dC D 8 + T cells was analyzed
by FACS. Representative data referring to the mean of data obtained from all the patients included in each group was shown. ∗P<. 05.Clinical and Developmental Immunology 5
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Figure 3: CpG-ODNs enhanced the local proliferation of CD4+ Tc e l l sa n dC D 8 + T cells. TILs were collected from lung cancer patients (n =
12) and treated with CpG-ODNs or control CpG-ODNs as described in Materials and Methods. 1 × 107 autologous TILs were transferred
into the tumor bearing Balb/c nude mice with 100ug CpG-ODNs or control CpG-ODNs through tail vein. Four days later, the recipients
were treated with 2mg BrdU i.p. every other day and up to a cumulative dose of 8mg BrdU. Eight hours after the last BrdU injection, the
lymphocytes were isolated from tumor mass and the proliferation of CD4+ T cells (a) and CD8+ T cells (b) was examined by FACS. ∗P<. 05.
foundthatthetumorgrowthwasdramaticallyreducedinthe
CpG-ODNs treated group compared with that of the TILs
transferred group and Control CpG-ODNs treated group
(Figure 1(a)). Moreover, the survival of tumor-bearing mice
was signiﬁcantly prolonged (Figure 1(b),d a y5 3v e r s u sd a y s
34 and 36, P<. 05). These results suggested that CpG-
ODNs could enhance the antitumor eﬃciency of adoptively
transferred TILs.
3.2. CpG-ODNs Enhanced the Activation Capacity of Adop-
tively Transferred TILs. Then, we investigated whether the
adoptively transferred TILs possessed the capacity for acti-
vation, which could contribute to antitumor eﬀects of TILs
in vivo. Ten days after transfer, the CD4+ T cells and CD8+
T cells were isolated from tumor mass and analyzed for their
expression of surface activation marker CD62L and CD44.
As shown in Figure 2(a),b o t hC D 4 + and CD8+ Tc e l l si n
the CpG-ODNs treated group expressed lower MFI (mean
ﬂuorescence intensity) of CD62L which represented higher
activation compared to the controls. In contrast, the expres-
sion of CD44 was signiﬁcantly higher in the CpG-ODNs
treated group (Figure 2(b), P<. 05). These data suggested
that the CpG-ODNs treated T cells possessed activation
capacity and displayed an eﬀector-memory like phenotype.
3.3. CpG-ODNs Enhanced the Proliferation Capacity of Trans-
ferred TILs. Next, we evaluated the proliferation capacity
of adoptively transferred TILs. Four days after transfer, the
tumor bearing nude mice were administrated with 2mg
BrdU every other day and up to a cumulative dose of 8mg
BrdU. Eight hours after the last BrdU injection, CD4+ T
cells and CD8+ T cells were isolated from the tumor mass
and analyzed for the incorporation of BrdU. Results shown
that the proportion of BrdU+ in CD4+ T cells in CpG-
ODNs treated group was higher than that in control groups
(Figure 3(a), 21.4% versus 11.3% and 11.6%, P<. 05).
Moreover, the proportion of BrdU+ in CD8+ T cells in CpG-
ODNs treated group also was higher than that in control
groups(Figure 3(b), 16.5% versus 10.1% and 9.7%, P<. 05).
These data suggested that CpG-ODNs could enhance the
proliferation of tumor inﬁltrating CD4+ T cells and CD8+
T cells.
3.4. CpG-ODNs Promoted Polarization towards Th1 Immune
Response of Transferred TILs. To gain an insight into whether
the adoptively transferred TILs could induce Th1 immune
response which dominated antitumor immunity, ten days
aftertransfer,theCD4+ TcellsandCD8+ Tcellswereisolated
from the tumor mass and analyzed for their production
of IFN-γ and IL-4. Results showed that the production of
IFN-γ in CD4+ T cells and CD8+ T cells was signiﬁcantly
higher in the CpG-ODNs treated group compared with
that of the control groups (Figures 4(a) and 4(c), P<. 05).
Reversely, the production of IL-4 in CD4+ T cells and CD8+
T cells was signiﬁcantly lower in the CpG-ODNs treated
group (Figures 4(b) and 4(d), P<. 05). These data suggested
that adoptive transfer of CpG-ODNs treated TILs skewed
the immune response towards Th1, which greatly improved
antitumor eﬃcacy.
3.5. CpG-ODNs Modiﬁed the Inﬁltration of Th17 Cells in
Tumor Mass. Accumulating data suggested that Th17 cells6 Clinical and Developmental Immunology
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Figure 4: CpG-ODNs enhanced the IFN-γ production of CD4+ Tc e l l sa n dC D 8 + T cells. TILs were collected from lung cancer patients (n =
12) and treated with CpG-ODNs or control CpG-ODNs as described in Materials and Methods. 1 × 107 autologous TILs were transferred
into the tumor bearing Balb/c nude mice with 100ug CpG-ODNs or control CpG-ODNs through tail vein. Ten days later, CD4+ Tc e l l s
and CD8+ T cells were isolated from tumor mass and their production of IFN-γ (a and c) and IL-4 (b and d) was detected by intracellular
staining. ∗P<. 05.
played a pivotal role in antitumor immunity [13–15]. To
assess the potential role of CpG-ODNs on Th17 cells in
adoptive transferred TILs, ten days after transfer, T cells
were isolated from the tumor mass and analyzed for the
proportionofTh17cellsusingﬂowcytometry.Wefoundthat
the proportion of Th17 cells in CD4+ T cellswas signiﬁcantly
higher in the CpG-ODNs treated group compared with that
of the control groups (Figure 5(b), 7.64% versus 2.17% and
2.06%, P<. 05). This result indicated that CpG-ODNs could
modify the inﬁltration of Th17 cells in tumor mass in vivo.
3.6. Inhibition of the Functional Activity of Th17 Cells
Abrogated CpG-ODNs Enhanced Antitumor Eﬃciency of
Transferred TILs. To evaluate the potential role of Th17
cells in the enhanced antitumor responses of TILs induced
by CpG-ODNs, two days after transfer, the recipients were
injected intravenously with anti-IL-17 (5ug/g) every seven
days, and then the survival time of tumor-bearing mice were
observed.Comparedwiththatofcontrolgroups,thesurvival
time in mice treated with IL-17 neutralizing antibodies was
signiﬁcantly reduced (Figure 6, day 40 versus days 48 and 49,Clinical and Developmental Immunology 7
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Figure 5: CpG-ODNs enhanced the inﬁltration of Th17 cells in tumor mass. TILs were collected from lung cancer patients (n = 12) and
treated with CpG-ODNs or control CpG-ODNs as described in Materials and Methods.1× 107 autologous TILs were transferred into the
tumor bearing Balb/c nude mice with 100ug CpG-ODNs or control CpG-ODNs through tail vein. Ten days later, the percentages of IL-17
positive cells in CD4+ T cells isolated from tumor mass were detected by ﬂow cytometry. Representative data from 12 individual patients
with lung cancer was shown (a), and the mean frequency of Th17 cells also was calculated, respectively (b). ∗P<. 05.
P<. 05), indicating that Th17 cells might play an important
role in the enhanced antitumor eﬃcacy of TILs induced by
CpG-ODNs.
4. Discussion
In the present study, we reported that CpG-ODNs could
enhance the antitumor eﬃcacy of adoptive transfer of TILs
into tumor-bearing nude mice which was accompanied by
increased activation and proliferation in both CD4+ and
CD8+ T cells, as well as the polarization of Th1 immune
response. More importantly, we found that CpG-ODNs
could modify the inﬁltration of Th17 cells in tumor mass,
which might contribute to the eﬃcacy of ACT.
Recently, CpG-ODNs were used as adjuvant in therapy
against infections and cancer [16, 17]. However, the direct
eﬀects of CpG-ODNs on eﬃciency of transferred TILs
remain unclear. It was reported that CpG-ODNs could
elevate the activity capacity of T cells in tumor mass [18,
19]. We extended previous ﬁnding by demonstrating that
the CpG-ODNs could enhance the antitumor eﬃcacy of
adoptive transferred TILs, which was correlated to enhanced
activity and proliferation of tumor inﬁltrating CD4+ Tc e l l s
and CD8+ T cells. It was consistent with our previous
observation that CpG-ODNs could enhance the antitumor
eﬀects of PBMCs [10]. In this study, we further reported that
CpG-ODNs could induce the Th1-type immune response
in TILs adoptively transferred recipients. These results were
consistent with other’s work which showed that CpG-ODNs
could stimulate the IFN-γ secretion of T cells and DCs in
tumor host [20].
Recent study suggested that Th17 cells, a distinct subset
of CD4+ T cells, inﬁltrated in tumor mass and played
a controversial role in tumor immunity [14, 15]. Some
research works reported that IL-17A, IL-23, and IL-6 could
promote tumor growth and/or impair the function of
eﬀector T cells, suggesting that Th17 cells might play a
negative role in antitumor immunity [21–23], while others8 Clinical and Developmental Immunology
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Figure 6: Neutralization of IL-17 reduced the survival of human
lung cancer bearing nude mice. TILs were collected from lung
cancer patients (n = 12) and treated with CpG-ODNs or control
CpG-ODNs as described in Materials and Methods.1× 107
autologous TILs were transferred into the tumor bearing Balb/c
nude mice with 100ug CpG-ODNs or control CpG-ODNs through
tail vein. After 2 days, the recipients were injected intravenously
with anti-IL-17 (5ug/g) every seven days. Then, the survival of
tumor bearing nude mice was observed.
showed that Th17 cells and Th-17 cell-associated cytokines
could elevate antitumor immunity in some certain animal
models [15, 24, 25]. Recent evidence further showed that
adoptive transferred Th17-polarized cells could reduce the
tumor growth in vivo [26]. Perhaps it reﬂected the fact
that Th17 cells might play distinct roles in antitumor
immune responses depending on the certain context of the
experimental conditions [27–30]. In our study, we found
that CpG-ODNs could elevate the inﬁltration of Th17 in
tumor mass. Most importantly, neutralization of biological
activity of IL-17 could signiﬁcantly reduce CpG-ODNs
enhanced eﬃciency of adoptive transferred TILs, suggesting
that Th17 contributed to the CpG-ODNs enhanced antitu-
mor immunity of adoptive transferred TILs. Consistently,
some researches found that endogenous IL-17 contributed
to reduced tumor growth and metastasis in vivo [24]. In
contrast, Muranski et al. reported that not IL-17 but IFN-γ
produced by Th17 cells contributed to tumor reduction [26].
WeproposedthatthepossibleroleofTh17-derivedcytokines
such as IL-17 and IFN-γ in Th17 cell-mediated antitumor
immunity might be dependent on their local concentrations,
bioavailability, and potential targets [31]. However, the exact
mechanism through which Th17 contributed to CpG-ODNs
enhanced antitumor immunity of ACT remains as a subject
to successive researches.
In conclusion, our study demonstrated that CpG-
ODNs could enhance the eﬃciency of adoptive transfer
immunotherapy using TILs in vivo via modifying the Th1
polarization and local inﬁltration of Th17 cells, which
might provide a useful strategic alternative for clinical
biotherapy.
5. Conclusions
CpG-ODNs could enhance the eﬃciency of adoptive cell
transfer immunotherapy based on tumor inﬁltrating lym-
phocytes by modifying Th1 type immune response and local
inﬁltration of Th17 cells in vivo.T h i ss t u d ym i g h tp r o v i d ea
clue for developing a useful strategic alternative for clinical
biotherapy for tumor patients.
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